Xin Gan

Xin Gan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
XLXiaoming Liu
Xiaoming Liu
JLJichun Liu
Jichun Liu
XZXuekang Zhang
Xuekang Zhang
YTYuben Tong
Yuben Tong
XGXin Gan
Xin Gan
Although the non‐small cell lung cancer (NSCLC) is one of the most malignant tumours worldwide, the mechanisms controlling NSCLC tumourigenesis remain unclear. Here, we find that the expression of miR‐520b is up‐regulated in NSCLC samples. Further studies have revealed that miR‐520b promotes the proliferation and metastasis of NSCLC cells. In addition, miR‐520b activates Hedgehog (Hh) pathway. Inhibitor of Hh pathway could relieve the oncogenic effect of miR‐520b upon NSCLC cells. Mechanistically, we demonstrate that miR‐520b directly targets SPOP 3′‐UTR and decreases SPOP expression, culminating in GLI2/3 stabilization and Hh pathway hyperactivation. Collectively, our findings unveil that miR‐520b promotes NSCLC tumourigenesis through SPOP‐GLI2/3 axis and provide miR‐520b as a potential diagnostic biomarker and therapeutic target for NSCLC.

1 December 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
JLJixiang Liu
Jixiang Liu
YZYulan Zhong
Yulan Zhong
SPShanshan Peng
Shanshan Peng
XZXiangxiang Zhou
Xiangxiang Zhou
XGXin Gan
Xin Gan
Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis Jixiang Liu, Yulan Zhong, Shanshan Peng, Xiangxiang Zhou, Xin Gan Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang University, Nanchang, China Background: PD1/PDL1 blockade is a promising treatment for patients with non-small-cell lung cancer (NSCLC). Here, we employed meta-analysis to evaluate the efficacy and safety of PD1/PDL1 blockades for previously treated NSCLC patients. Methods: Randomized clinical trials were retrieved by searching electronic databases. Data for HRs, 95% CIs for overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were extracted and pooled. Results: A total of five randomized controlled trials including 2,910 patients were included in this meta-analysis. Pooled HRs (95% CI) were 0.71 (0.63–0.79, P<0.0001) for OS and 0.86 (0.73–1.02) for PFS. In the subgroup analysis, the pooled HR (95% CI) for PFS was 0.82 (0.75–0.91, P<0.0001) in patients with high PDL1 expression, but no significant difference was seen in patients with low expression (0.97 [0.76–1.24], P=0.82). The pooled RR for treatment-related AEs of all grades was 0.32 (0.27–0.38, P<0.00001) compared with the docetaxel arm, while that for grade 3–5 treatment-related AEs in the PD1/PDL1-blockade arm was 0.16 (0.10–0.27, P<0.00001). Conclusion: PD1/PDL1 blockades enhanced OS and PFS and led to lower risk of AEs in NSCLC patients. Smoking history and wild-type EGFR were associated with extended OS. Keywords: non-small-cell lung cancer, checkpoint immunologic treatments, PD1, PDL1, meta-analysis

2 May 2022 in Bioengineered
Verified
Journal Article
Open access
YZYuanzhe Zhu
Yuanzhe Zhu
HWHuala Wu
Huala Wu
XYXi Yang
Xi Yang
ZXZhijuan Xiong
Zhijuan Xiong
TZTiantian Zhao
Tiantian Zhao
XGXin Gan
Xin Gan
The long non-coding RNA (lncRNA) LINC00514 was identified to play an essential oncogenic function in different human cancers, but its effects in non-small cell lung cancer (NSCLC) are yet to be elucidated. In this study, we evaluated the function of LINC00514 in NSCLC. LINC00514 expression and prognosis in NSCLC were analyzed using qRT-PCR and online bioinformatic tools. The bioeffects of LINC0514 in NSCLC cells were examined using cell counting kit-8, colony formation, and transwell assays. Western blotting was used to measure the expression of the target proteins. The LINC00514 regulation of the Wnt/β-catenin signaling pathway was assessed using a specific agonist (LiCl) and luciferase reporter assay. We found that LINC00514 expression was elevated in NSCLC cells and clinical samples and that increased LINC00514 expression predicted poorer patient prognosis. Silencing LINC00514 suppresses proliferation, migration, and invasion of NSCLC cells. Downregulation of LINC00514 inhibited Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT). Moreover, suppression of the biological phenotypes of NSCLC cells induced by LINC00514 gene silencing was restored after LiCl treatment. Finally, we found that silencing LINC00514 attenuated the growth of xenograft tumors in vivo. Altogether, this study provides the latest convincing evidence that LINC00514 facilitates the malignant biological behavior of NSCLC cells through activation of the Wnt/β-catenin pathway, which might offer a beneficial approach for the treatment of NSCLC. Graphical abstract

2 June 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
XLXiaoming Liu
Xiaoming Liu
YHYan Hu
Yan Hu
BYBentong Yu
Bentong Yu
KPKai Peng
Kai Peng
XGXin Gan
Xin Gan
Lung adenocarcinoma (LUAD) is one of the important components of non-small-cell lung cancer (NSCLC) and leads to many deaths every year. During the initiation and progression of the LUAD, the Hh-GLI2 pathway plays critical roles. Several components of this pathway have been shown to be amplified or overexpressed in LUAD, providing this pathway as an attractive target for therapeutics. However, a gap in our understanding of the Hh-GLI2 pathway is the identity of transcriptional targets of GLI2 that drive LUAD tumorigenesis. Here, we show that the oncogene CRKL is a direct target of GLI2. GLI2 turns on CRKL transcription through binding its second intron. Furthermore, CRKL is an essential mediator for GLI2-driven proliferation and migration of LUAD cells. Depletion of CRKL blunts Hh-GLI2 pathway-mediated cell proliferation and invasion. Lastly, we find that CRKL knockout cells are more sensitive to EGFR-TKI and chemotherapeutics. Taken together, our work here identifies a specific target for Hh-related malignancies and provides CRKL as a promising therapeutic target for LUAD.

1 November 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
LLLu Liu
Lu Liu
CWChaoling Wu
Chaoling Wu
ZZZhiyan Zhang
Zhiyan Zhang
XJXinxing Jin
Xinxing Jin
QZQi Zou
Qi Zou
JTJianlin Tong
Jianlin Tong
Background: Chronic obstructive pulmonary disease (COPD), the third leading cause of global mortality, imposes substantial socioeconomic burdens. Existing therapies, such as smoking cessation and non-invasive ventilation, primarily alleviate symptoms without arresting disease progression. Comorbidities, including cardiovascular disease and metabolic syndrome, exacerbate functional decline, yet the causal role of dyslipidemia in COPD pathogenesis remains unclear. This study seeks to establish a causal link between hypercholesterolemia and COPD while identifying potential biomarkers and therapeutic targets. Methods: Leveraging cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), we employed Mendelian randomization (MR) analysis using 71 single-nucleotide polymorphisms (SNPs) associated with hypercholesterolemia, integrated with bioinformatics tools for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Demographic variables (age, sex, body mass index [BMI]) and dietary factors were compared between COPD patients and controls. Results: Univariate analyses identified significant differences in demographics and dietary patterns between COPD and non-COPD groups (P < 0.05). Multivariate logistic regression revealed: (1) a reduced risk of COPD with elevated total cholesterol levels (odds ratio [OR]: 0.815, 95% confidence interval [CI]: 0.721– 0.923, P = 0.001); and (2) increased COPD risk associated with higher age and BMI. Bioinformatics analyses pinpointed atorvastatin, fenofibrate, and pravastatin as candidate therapeutics. Gene interaction networks and pathway enrichment highlighted roles for lipid homeostasis and cholesterol metabolism. Conclusion: Analysis of NHANES data demonstrates an inverse association between cholesterol levels and COPD prevalence, with MR confirming a causal relationship. These findings underscore targetable pathways and suggest repurposing statins and fibrates, meriting further mechanistic studies and clinical trials for validation.

1 January 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
HWHuala Wu
Huala Wu
YZYulan Zhong
Yulan Zhong
YLYangjingsi Li
Yangjingsi Li
XZXiangxiang Zhou
Xiangxiang Zhou
TZTiantian Zhao
Tiantian Zhao
XGXin Gan
Xin Gan
Background: Bone marrow mesenchymal stem cell (BMSC) therapy is a novel approach for treating COPD. However, the difficulty in engraftment and easy clearance of BMSCs in vivo has hindered their clinical application. Hence, exploring effective methods to improve the engraftment and differentiation rates of BMSCs in vivo is urgent. Methods: We constructed BMSCs overexpressing Wnt3a by lentivirus infection and transplanted them into a COPD rat model. The damage level of COPD rat lung tissue was assessed by pathology analysis and inflammatory cytokines analysis. The engraftment of BMSC was detected by immunofluorescence staining. Statistical analysis was performed using GraphPad Prism 7. Results: We found that Wnt3a significantly enhanced the engraftment rate of BMSCs in the lungs of rats and further increased their differentiation rate into type II alveolar epithelial cells. We also assessed the expression of inflammatory factors in the lung tissues of COPD rats and discovered that Wnt3a reduced the levels of the inflammatory factors IL-6 and IL-1β while increasing the level of the anti-inflammatory factor IL-10. Our study demonstrates that Wnt3a can improve the engraftment and differentiation rates of BMSCs in the host and further alleviate COPD symptoms by regulating the secretion of inflammatory factors. Conclusion: Constructing BMSCs overexpressing Wnt3a could serve as a new strategy for stem cell therapy in COPD.